Andrew Burritt
Senior Director, Chemistry Plexium Inc.
Prior to joining Plexium in 2021, Andrew spent over 20 years working in various companies in the pharmaceutical industry, including BMS and Dart Neuroscience. His work has predominantly focused on early lead discovery and hit optimization for targets within oncology and neuroscience. Andrew earned his B.Sc. (hons) and Ph.D. from the University of Canterbury, New Zealand.
Seminars
Monday 27th October 2025
Application of Plexium’s Picowell Screening Technology to the Identification of Helios Molecular Glue Degraders
10:00 am
- Application of Plexium’s proprietary ultrahigh density Picowell screening technology to the identification of cereblon mediated molecular glue degraders (MGDs) of Helios (IKZF2) will be described
- Hits from the screen were shown to bind to cereblon, and degradation of Helios was independently confirmed in a Helios-GFP assay and by global proteomics. Loss of Helios was rescued by co-treating with a proteasome inhibitor confirming dependence on the ubiquitin proteasome system
- Collectively, these results demonstrate that Plexium’s Picowell screening platform enables the discovery of MGDs of Helios
